Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy ...Middle East

RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and...

Hence then, the article about regor announces promising safety and single agent efficacy data evaluating rgt 419b in hr her2 advanced breast cancer patients who have progressed on cdk4 6 inhibitors and endocrine therapy was published today ( Friday 08/12/2023 - 02:41 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy )

Also on site :

• What to Know About Allegations of Excessive Drinking by FBI Director Kash Patel
• Gunman opens fire and seizes supermarket in Kiev (VIDEOS)
• The Critically Acclaimed 2012 Best-Seller Named the 'Best Novel of the Century': 'Every Word is Finely Tuned'